Open-label Study of Liothyronine in MS

Completed · Phase 1

Conditions studied: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive

In brief

This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.

Key facts

Study ID

NCT02506751

Run by

Johns Hopkins University

People needed

20

Starts

2015-07-01

Expected to finish

2017-09-18

Last updated by the study team

2018-02-12

Who can join

Age: 18 and older, up to 58. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must meet 2010 McDonald criteria for clinically definite MS
• Must be euthyroid
• Expanded Disability Status Scale (EDSS) 3.0-7.5
• Patients may be on MS immunomodulating therapies or immunosuppressant therapies during the study

You may not qualify if…

• Known thyroid disease (past or current)
• Currently on thyroid replacement therapy
• Steroid use within a month of screening
• History of coronary artery disease, atrial fibrillation, or other clinically significant cardiac disease
• History of adrenal insufficiency
• Ongoing renal and/or liver disease
• Ongoing severe depression and/or anxiety
• Use of carbamazepine, phenytoin, phenobarbital, warfarin, antacids, cholestyramine, colestipol, sucralfate, and rifampin
• Known contraindication to using beta-blocker medications
• History of alcohol or substance abuse in the past 6 months
• Pregnant or nursing
• If the investigator feels that participation in this study is not in the best interest of the subject

Where it is running

• The Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.